A1M Pharma carries out a rights issue and prepares for a listing change to NASDAQ First North
The company was founded in 2008 by researchers at Lund University, Sweden. The company develops and commercializes medical applications based on the body's own protein A1M. The main focus of the company is currently on the treatment of preeclampsia and kidney damage.
The company has published a prospectus for the rights issue with a subscription period running from March 24 to April 7. A listing change to NASDAQ First North is expected in June. Today, A1M Pharma is listed on AktieTorget. At full subscription, the company will obtain approximately SEK 123 million.
MAQS’ team comprised lead partner Ulf Yxklinten, partners Patrik Gustafsson Sonne and David Berggren, and associate Lejla Fazlinovic.